4 December 2015 - PHARMAC is pleased to announce the approval of proposals to fund two new treatments for Multiple Sclerosis (MS) – dimethyl fumarate and teriflunomide – and to make amendments to the Special Authority criteria relating to MRI requirements for all MS treatments.

For more details, go to: http://www.pharmac.health.nz/news/notification-2015-12-04-multiple-sclerosis/